A Phase 1, Open-label, Randomized Crossover Study, in Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single 500-mg Dose of JNJ-53718678 Administered as (an) Oral Concept Formulation(s) Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of (an) Oral Concept Formulation(s)
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2017
At a glance
- Drugs JNJ 53718678 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 04 Dec 2017 Planned End Date changed from 6 Mar 2018 to 1 Oct 2018.
- 22 Nov 2017 Planned number of patients changed from 48 to 96.
- 22 Nov 2017 Planned End Date changed from 1 Mar 2018 to 6 Mar 2018.